Hormone Replacement Therapy in Menopause: Who Should Consider It, When, and What's the Real Risk?

In July 2002, American media carried a story that reshaped how millions of women around the world thought about menopause within a matter of months: a large randomized trial, the Women's Health Initiative (WHI), was stopped earlier than planned after women taking hormone replacement therapy showed elevated rates of breast cancer, heart attack, stroke, and blood clots. Within the following year, HRT prescriptions in the US fell by more than half — and stayed low for the next two decades.

The problem is that the 2002 headlines significantly oversimplified what the study actually found. Twenty years of further analysis of that same cohort, newer trials, and updated clinical guidelines have drawn a far more measured picture — one that depends above all on how old a woman is, and how long after her last period, when she starts therapy. This distinction, now known as the "timing hypothesis," is the key to understanding why what you might read on a forum post from 2004 could be outdated in 2026.

WHI was, in fact, two parallel trials: one tested estrogen plus progestin in women with an intact uterus, the other estrogen alone in women who had had a hysterectomy. It was the first of these, stopped in 2002, that triggered the panic. It's worth looking at the absolute numbers, not just the relative risk increase that dominated the headlines.

In 2013, the same WHI research team published an extended analysis covering data from the intervention phase plus over a decade of further follow-up after the trial ended. This time, results were broken down by age and time since menopause at the start of therapy — and the picture looked quite different from the 2002 headlines.

The timing hypothesis originates from animal studies: estrogen given early, before atherosclerosis has developed in the blood vessels, appears to have a protective effect on the vascular endothelium, whereas the same hormone given to already-advanced, unstable atherosclerotic plaque may act the opposite way — destabilizing it. In humans, this translates into a practical conclusion: a woman starting HRT shortly after menopause likely has a different, more favorable cardiovascular risk balance than a woman starting the same therapy a decade or two later.

The Menopause Society (formerly the North American Menopause Society, NAMS) — the leading US scientific body on menopause — periodically updates its HRT position based on the totality of available evidence, not WHI alone. Its 2022 statement remains the current reference point.

This position isn't an outlier — European gynecological and endocrinological societies draw similar conclusions, with the same emphasis on individualizing the decision. The common thread across current guidelines: HRT is no longer treated as unambiguously "dangerous" or unambiguously "safe for everyone" — it's an intervention whose balance depends on the specific patient, her age, time since menopause, and individual risk profile.

It's worth stressing: a "favorable balance" doesn't mean zero risk. It means that, in this specific age and clinical group, the benefits — symptom relief, bone protection, and for some women, better sleep and mood — outweigh the absolute risk increase, which in this group remains relatively small.

In some of these situations HRT isn't automatically ruled out — for example, women with a prior venous thromboembolism may, in some cases, consider transdermal forms with a lower clotting risk under close specialist supervision — but that's always a decision requiring individualized, specialist evaluation, not a choice made independently based on general information.

This is one of the aspects of HRT least often explained in simplified overviews, yet it has real clinical significance: oral estrogen passes through the liver (the so-called first-pass effect) and increases clotting factor production more than estrogen delivered through the skin, which bypasses that stage of liver metabolism.

In women with an intact uterus, estrogen is always paired with a progestogen — using estrogen alone with an intact uterus significantly raises the risk of endometrial hyperplasia and cancer. The choice of progestogen (micronized progesterone versus synthetic progestins) is another variable a physician weighs individually, partly based on tolerability and the patient's risk profile.

The 2002 panic around HRT had real consequences — for two decades, many women with bothersome menopause symptoms avoided a therapy that could have meaningfully improved their quality of life, based on data that, in light of today's knowledge, turned out to be incomplete. At the same time, HRT isn't a risk-free intervention, and the decision to start it — especially for women with a complicated history or starting later — requires a substantive, individualized conversation with a physician, not automatic uptake or automatic avoidance.